AstraZeneca resumes its trials after clearance | Arriba Trends

AstraZeneca resumes its trials after clearance

AstraZeneca has confirmed the status of its Oxford coronavirus vaccine AZD1222, after receiving the green signal from the UK authorities to restart its trails. Earlier all the activities related to the trial were paused to carry out the standard review process to confirm the safety of the trails by the independent committees and the international regulators. The trials of AZD1222 have started again in the UK after it received the confirmation by the Medicines Health Regulatory Authority which said doing the trial was safe. The UK’s Secretary of State for Health Matt Hancock shared the recent development through his tweet.

Later the University of Oxford released an official statement stating about the reviewing of the trials. It stated, “This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the studies, while it is investigated, ensuring we maintain the integrity of the trials. In large trials illnesses will happen by chance but must be independently reviewed to check this carefully“.

It is to be noted that the phase I trial of the vaccine began in April 2020, since then nearly 18,000 individuals all over the globe have been part of the study vaccine trials till now and more than 1,000 immunisations are done in UK.

Share
Translate »